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Background: Clinical trials require cost-effective methods for identifying, randomising, and following large
numbers of people in order to generate reliable evidence. ASCEND (A Study of Cardiovascular Events iN Diabetes)
is a randomised ‘2 × 2 factorial design’ study of aspirin and omega-3 fatty acid supplements for the primary
prevention of cardiovascular events in people with diabetes; this study used central disease registers and a mail-
based approach to identify, randomise, and follow 15,000 people. In collaboration with UK consultants and general
practitioners (GPs), researchers identified potentially eligible people with diabetes from centrally held registers
(e.g. for retinopathy screening) and GP-held disease registers. Permission was obtained under section 251 of the
National Health Service Act 2006 (previously section 60 of the NHS act 2001) to allow invitation letters to be
generated centrally in the name of the holder of the register. In addition, with the collaboration of the National
Institutes for Health Research (NIHR) Diabetes and Primary Care Research Networks (DRN and PCRN), general
practices sent pre-assembled invitation packs to people with a diagnosis of diabetes. Invitation packs included a cover
letter, screening questionnaire (with consent form), information leaflet, and a Freepost envelope. Eligible patients
entered a 2-month, pre-randomisation, run-in phase on placebo tablets and were only randomised if they completed a
randomisation form and remained willing and eligible at the end of the run-in. Follow-up is ongoing, using mail-based
approaches that are being supplemented by central registry data.
Results: Information on approximately 600,000 people listed on 58 centrally held diabetes registers was obtained, and
300,188 potentially eligible patients were invited to join the study. In addition, 785 GP practices mailed invitations to
120,875 patients. A further 2,340 potential study participants were identified via other routes. In total, 423,403 people
with diabetes were invited to take part; 26,462 entered the 2-month, pre-randomisation, run-in phase; and 15,480 were
randomised.
Conclusion: If sufficient numbers of potentially eligible patients can be identified centrally and the trial treatments do
not require participants to attend clinics, the recruitment and follow-up of patients by mail is feasible and cost-effective.
Wider use of these methods could allow more, large, randomised trials to be undertaken successfully and cost-effectively.
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methodologyBackground
Randomised controlled trials are the cornerstone for reli-
ably evaluating the safety and efficacy of therapeutic strat-
egies [1]. For chronic conditions, where many treatments
are expected to have only moderate effects, trials need to
be large in size and long in duration to achieve sufficient
statistical power and ensure a robust result. The regula-
tions surrounding clinical trials are becoming increasingly
burdensome [2, 3], and as a result, the cost and complex-
ity of a standard approach to evaluating therapies is pro-
hibitive (typically at least £3–400 M for large clinical
outcome trials), and the model is unsustainable [4]. The
development of potentially effective drugs is often stopped
prematurely on financial, rather than scientific grounds,
and it has become more difficult to do academic trials of
important scientific questions; this difficulty has resulted
in the distortion of the scientific agenda.
Clinical trials are typically undertaken in a clinic-based
setting either in primary or secondary care, and the re-
cruitment of large numbers of participants may require
many sites, resulting in organisational complexity and
very substantial costs [4]. However, for interventions
that require no ongoing physical or laboratory safety
monitoring, conducting the trial by mail offers a cost-
effective alternative. Several large, successful, rando-
mised trials have been conducted using both a mailed
drug supply and follow-up [5–8]. Experience from these
studies shows that, with appropriate attention to the
wording of the information leaflets, consent forms and
questionnaires, good response rates and compliance can be
achieved, and reliable information about medical events,
gathered. However, previous trials had been conducted
among healthcare professionals (i.e. doctors or nurses), and
it was not known if such mail-based approaches to clinical
trials would be feasible and acceptable in people without
such a background.
ASCEND (A Study of Cardiovascular Events iN Dia-
betes) is a 2 × 2 factorial design randomised study to as-
sess whether aspirin 100 mg daily versus placebo and
separately, omega-3 fatty acids 1 g daily versus placebo,
reduce the risk of cardiovascular events in individuals
with diabetes who do not already have diagnosed occlu-
sive arterial disease, and whether any such benefits out-
weigh any hazards from bleeding. To minimise costs
sufficiently to allow ASCEND to be funded by non-
commercial sources, the study was designed to be run
mainly by mail with back-up from a 24-hour Freefoneservice. The rationale and design are available on the
study website (http://www.ctsu.ox.ac.uk/ascend/further_-
pro.htm). This report describes the highly cost-effective
mail-based-recruitment methods, which allowed the ran-
domisation of 15,480 people with diabetes from around
the UK into ASCEND, making it one of the largest ever
trials in this patient group.
Methods
Trial coordination and approvals
The University of Oxford’s Clinical Trial Service Unit &
Epidemiological Studies Unit (CTSU) is coordinating the
study and has overall responsibility for the administration
and management of the study under the guidance of a
Trial Steering Committee. The University of Oxford is the
regulatory sponsor of the trial. After the study had secured
initial funding from the British Heart Foundation and a
commitment to provide packaged aspirin and matching
placebo tablets from Bayer Pharmaceuticals and omega-3
fatty acid capsules and matching placebo capsules from
Solvay Pharmaceuticals (subsequently Abbott and now
Mylan), Multi-centre Research Ethics Committee (MREC)
approval was obtained in 2003 (North West REC, ref 03/
8/087) for the study protocol and, in particular, to use cen-
trally held diabetes registers to identify potential partici-
pants. Since local doctors were not directly involved in
recruitment, the MREC approval indicated that local
ethics committees need only be informed of the study,
and site-specific approval was not required. Regulatory ap-
proval was obtained from the Medicines and Healthcare
Products Regulatory Agency (MHRA), and permission to
obtain identifiable details of people with diabetes without
their explicit consent (in order to invite them to partici-
pate in the trial) was obtained from the Patient Informa-
tion Advisory Group (PIAG), constituted under Section
60 of the NHS Act 2001 (subsequently the National Infor-
mation Governance Board under section 251 of the
National Health Service Act 2006, and more recently the
Confidentiality Advisory Group). The coordinating centre
ensured that the necessary Research Governance approvals
were also in place for the invitations to be sent from gen-
eral practices.
Identification of participants
People with diabetes were identified from two main
sources: (1) centrally held diabetes registers and (2) gen-
eral practice diabetes registers. Once potentially eligible
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processes were identical for each route of identification
(Fig. 1).
Centrally held registers
Consultant diabetologist physicians and other relevant doc-
tors from around the UK were invited to collaborate with
the investigators in Oxford in order to allow invitation of
potentially suitable individuals with diabetes from their lo-
cally held diabetes registers (such as those held for retinop-
athy screening). To streamline the invitation process, and
in accordance with the PIAG approval, the individuals’
contact details, date of birth, and GP details were sought
electronically, and lists were sent to the coordinatingFig. 1 Main routes of identification and invitation of potential study participan
separate application process. More recently it has become integrated with the
trust (PCT) in England, health board in Scotland and local health board in Wale
Research Authority); PIAG: Patient Information Advisory Group; NIGB: National I
Health and Social Care Information Centrecentre. Prior to contacting anyone, lists of potential invitees
were sent to the relevant GP asking that they inform the
coordinating centre if they did not wish their patients (ei-
ther specific individuals or all potentially eligible patients)
to be contacted about the study. No response from the GP
after a reminder letter was taken as agreement to contact
the patients. Immediately prior to the invitation being sent,
the vital status of the person was checked with the Office
for National Statistics (subsequently Health and Social
Care Information Centre), to help avoid inadvertent invita-
tion of people who had died (although delays in the avail-
ability of up-to-date information could not prevent this
entirely). Large-scale, automated, mailing systems were
used to generate individualised invitation letters, whichts. * At the time of recruitment for ASCEND, PIAG/NIGB approval was a
central IRAS system.** ASCEND sought local R&D from every primary care
s [13]. NRES: National Research Ethics Service (now part of the Health
nformation Governance Board; ONS: Office for National Statistics; HSCIC:
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designated holder of the diabetes register. The invitation
pack included the signed cover letter, a screening question-
naire (including the consent form), the study patient infor-
mation leaflet and a Freepost return envelope addressed to
the coordinating centre (see Additional files 1 and 2). A
24-hour Freefone telephone service was available for trial-
related enquiries from both potential participants and
medical staff.General practice registers
Consultants and other collaborators were also asked to
identify 20–30 local GPs with computerised disease reg-
isters and to seek their agreement to mail invitations to
potentially eligible individuals. In addition, the National
Institutes for Health Research (NIHR) Diabetes Research
Network (DRN) and the NIHR Primary Care Research
Network (PCRN) identified other interested general
practices and provided support for practice staff in the
recruitment process. Staff in collaborating practices per-
formed an electronic search on their practice database
for potentially eligible patients. Having reviewed the list
generated by this search to remove anyone considered
unsuitable for the trial, they informed the coordinating
centre of the number of invitation packs required, and
these were sent to the practice. At the practice, an ap-
proved invitation letter was mail-merged with the pa-
tient’s name and address onto practice headed paper,
and these invitation letters were added to the invitation
packs provided by the coordinating centre and mailed. For
practices identified via the DRN and PCRN, local network
support funding was available to help with these adminis-
trative tasks.Other identification routes
Other potentially eligible patients with diabetes were
identified from among participants in the Medical
Research Council/British Heart Foundation (MRC/
BHF) Heart Protection Study (HPS) [9], and they were
sent similar invitation packs, with the cover letter
adapted accordingly. In addition hospital-based collab-
orators were sent pre-assembled invitation packs that
they could hand to potentially eligible patients seen in
their outpatient clinics, and randomised participants
had the option of recommending a friend or relative
they thought might be eligible and interested in partici-
pating in the study. With their friend’s or relative’s per-
mission, their contact details were sent to the
coordinating centre, and an invitation pack was mailed
directly to the individual. The study website also facili-
tated the registration of potential volunteer partici-
pants. Diabetes UK, the UK patient, healthcare
professional, and research charity, published a briefarticle about the study in their patient magazine
‘Balance’, which resulted in a number of ‘self-referrals’.
Method of recruitment
People were potentially eligible if aged over 40 years,
had type 1 or 2 diabetes, and were not thought to have
occlusive vascular disease. Preliminary eligibility was
based on information provided on the completed screen-
ing questionnaire (i.e. confirmation of diabetes diagnosis,
no reported history of diagnosed occlusive arterial dis-
ease, no contraindication to regular aspirin, and signed
consent to participate – see Additional file 1). Com-
pleted screening questionnaires were returned (Freepost)
to the coordinating centre where they were logged and
then scanned using optical character recognition soft-
ware to facilitate the efficient transfer of information
into the study databases. Bespoke computer programs
were used to validate the data, with study administra-
tors, nurses, or clinicians performing additional checks
where needed or contacting participants for clarification
of responses if necessary.
Consent and pre-randomisation run-in
The screening questionnaire included specific questions
related to consent (Additional file 1), which the partici-
pants had to sign to confirm that they had understood,
and that if they had any questions, these had been ad-
dressed by study staff. The 24-hour Freefone service was
available if they had any questions about the trial or
wished to speak to a doctor about their involvement.
During the day, this was manned by the study team, and
outside working hours, a clinician was available via a
radio pager. Based on the screening questionnaire re-
sponses, willing and eligible patients, all of whom had
provided signed informed consent, entered a 2-month,
placebo, run-in phase (single-blind) and were mailed a
pre-randomisation ‘run-in’ pack of medication, which
contained 8-weeks of placebo aspirin and placebo
omega-3 fatty acids (Fig. 2). An information sheet about
the medication was provided (including a list of contra-
indicated medications – see Additional file 3), along with
a copy of the scanned image of their signed agreement
to participate.
The purpose of the run-in was to check that patients
would take the study medication and return the question-
naires regularly, thereby aiming to increase the chance
that, if randomised, they would remain compliant and
complete follow-up [10]. The run-in also provided the
time and opportunity for the coordinating centre to in-
form the GP of their patient’s provisional agreement to
enter the study, with an option for the GP to advise
against it if they wished, and for the coordinating centre
to send a blood and urine kit (see below) to the participant
to obtain baseline biological samples.
Fig. 2 Packaged study drugs for mail-based trial
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was sent with a supplementary information leaflet and
consent form (Fig. 3 and Additional file 4). Participants
were asked to take this kit to their general practice for
sample collection and the samples were then mailed to the
central laboratory in the containers provided. With theFig. 3 Blood and urine sampling kit for mail-based trialexception of those practices in which phlebotomy services
were very limited, this approach was widely accepted, and
most practices agreed to provide this service without
requesting additional payment. The practice nurse was also
asked to record the patient’s blood pressure and height and
weight on the form provided. This allowed minimised
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(e.g. lipids, HbA1c) as well as the collection of samples for
long-term storage and future analyses (including DNA).
Approximately 2 months after entering the run-in, the
participants were sent a randomisation questionnaire to
confirm their eligibility, collect more detail about their
diabetes and current medications, and check their com-
pliance with the study treatments during the run-in
period (Additional file 5). Participants were randomised
if they completed and returned a randomisation form
and remained willing and eligible to participate.
Results
A total of 423,403 potentially eligible individuals were
invited via the different routes, of which, 29 % (121,254
people) returned the screening questionnaires to the co-
ordinating centre (Table 1). Approximately one-third of
those returning the questionnaire agreed to join the trial.
After review of the questionnaire data, 26,462 partici-
pants (6 % of those originally invited) were willing and
eligible to join ASCEND and entered the 2-month run-
in period.
Randomisation questionnaires were sent to 22,579 pa-
tients. Of these, 15,480 people returned a completed ques-
tionnaire, remained willing and eligible to participate, and
were randomised into ASCEND using a computer-based
minimisation algorithm. Approximately 40 % of all patients
who entered the run-in dropped out before randomisation,
and half of these (approximately 5500 participants) had no
clinical reason to stop the trial but simply declined to con-
tinue. Overall, 4 % of those invited were randomised: 3 %
from centrally held registers (9013 patients) and 5 % from
GP registers (6037 patients).
The recruitment process took longer than expected
(Fig. 4) but accelerated after mid-2009 due to both the in-
creased availability of the large central registry data (re-
gional retinopathy registers) and to the support from the
DRN and PCRN. More than 700 general practices helped
with recruitment for the study, from which approximately
6000 of the randomised patients were identified. The ma-
jority of practices were identified with the help of the net-
works, whose support of ASCEND resulted in more than
5000 participants being recruited into the study (Table 2).Table 1 Recruitment by route of identification
Central registers General prac
Invited 300,188 120,875b
Returned valid screening form 100,563 19,478
Entered run-in 16,091 9739
Sent randomisation form 13,481 8541
Randomised (% of those invited) 9013 (3 %) 6037 (5 %)
aMRC/BHF Heart Protection Study/self-referral/Friends & Family referral/consultant c
bBased on number of screening forms sent by coordinating centre to GP practicesIf a completed screening questionnaire was not received
within approximately 2 weeks of the initial invitation from
a centrally held register, a reminder questionnaire was
sent. Approximately one-fifth (38,785 of 203,083) of those
who received a reminder returned either the original or
the reminder screening questionnaire. Similarly, a re-
minder was sent if a randomisation questionnaire was not
returned within 2 weeks. Approximately two-thirds (3110
of 5101) of those to whom randomisation questionnaire
reminders were sent, replied, and this led to 2183 patients
being randomised. Overall, nearly half (4111 of 9013) of
all randomised patients recruited via the centrally held
register route were sent a reminder for at least one of the
questionnaires.
The availability of information (e.g. sex, date of birth,
and post code) from the centrally held registers allows
the response rate to the invitation to be compared
among the different types of people (Table 3). Younger
invitees were more likely to express an interest in par-
ticipating in the study, even if they were not eligible
based on their returned screening form (14 % of those <
50 years old vs 7 % of those ≥ 70 years old, trend p value
< 0.0001). However, amongst people who were eligible
for the trial and entered the run-in phase, the percent
randomised did not vary substantially according to age.
There was also a slightly better initial response from
men than women (11 % vs 8 %, chi-square p < 0.0001),
but when those who were ineligible at screening are taken
into account, the proportion randomised of those entering
run-in was similar by sex (56.2 % men vs 55.5 % women,
chi-square p = 0.4) (Table 3).
A particular advantage of the mail-based trial method-
ology used in ASCEND is that with no requirement to at-
tend study clinics, participation is not limited by
geographical proximity to a study centre. Figure 5 shows
the location of the home addresses of the randomised par-
ticipants in ASCEND, with recruitment covering both
rural and urban areas across the UK. The response to invi-
tation was slightly greater from those living in rural areas
compared with those in cities (10.9 % vs 9.7 %, p < 0.0001,
Table 3). This is likely to be in part due to differences in
the Townsend index (a measure of material deprivation
based on the subject’s home post code), in which atitioner (GP) registers Othersa Total (% of those invited)
2340 423,403
1213 121,254 (29 %)
632 26,462 (6 %)
557 22,579 (5 %)
430 (18 %) 15,480 (4 %)
linic invitations
to be mailed to participants
Fig. 4 Cumulative recruitment of study participants by year
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in the least deprived areas to 8 % from the most deprived
areas (trend p value < 0.0001, Table 3). However, a highly
significant rural vs urban effect still persists after allowing
for Townsend index (p < 0.0001).
The number of days between mailing a study invitation
and receipt of the response could be recorded for screen-
ing questionnaires sent by the coordinating centre and for
all randomisation questionnaires. The mean (SD) time
from original invitation to response was 24 (27) days and
14 (15) days for the screening and randomisationTable 2 Number of GP practices identified and participant recruitm
Research Network (DRN) and other routes




Total 785 120,875questionnaires, respectively. To keep study costs down,
second class postage was used for all routine mailings, so
the minimum achievable response time was, therefore,
4 days. Ninety-five percent of responses to the screening
and randomisation questionnaires were received within
approximately 2 months and 1 month, respectively.
A 24-hour Freefone telephone service for queries from
participants or their doctors was available to support the
recruitment process. Over the 6-year recruitment phase,
8800 telephone calls were logged to this service: 3500
were incoming calls with enquiries from participants orent via the Primary Care Research Network (PCRN), Diabetes
ited Number of patients
entered run-in
Number of patients randomised
(% of those invited)
6733 4207 (5 %)
1772 1065 (4 %)
1234 765 (5 %)
9739 6037 (5 %)
Table 3 Response to invitation; entering pre-randomisation run-in phase; and randomised by age, sex, and Townsend Index (central
register route only)






Percent of those entering run-in
who are subsequently randomised
Age (years)b
<50 12,753 1,729 (14 %) 1,262 (10 %) 694 (5 %) 55 %
≥50, < 60 59,635 7,580 (13 %) 4,914 (8 %) 2,801 (5 %) 57 %
≥60, < 70 93,526 11,040 (12 %) 6,103 (7 %) 3,543 (4 %) 58 %
≥70 134,274 9,508 (7 %) 3,812 (3 %) 1,975 (1 %) 52 %
Sex
F 130,889 10,642 (8 %) 5,931 (5 %) 3,297 (3 %) 56 %
M 169,299 19,215 (11 %) 10,160 (6 %) 5,716 (3 %) 56 %
Townsend Indexc
< -3 64,054 7,635 (12 %) 4,649 (7 %) 2,781 (4 %) 60 %
≥ -3 < 0 100,057 10,544 (11 %) 6,022 (6 %) 3,467 (3 %) 58 %
≥0 < 2 47,597 4,207 (9 %) 2,179 (5 %) 1,201 (3 %) 55 %
≥2 < 4 41,932 3,576 (9 %) 1,697 (4 %) 838 (2 %) 49 %
≥4 < 6 30,637 2,466 (8 %) 1,009 (3 %) 496 (2 %) 49 %
≥6 15,354 1,287 (8 %) 458 (3 %) 195 (1 %) 43 %
Urban/rural locationd
Urban 244,718 23,729 (10 %) 12,590 (5 %) 6,960 (3 %) 55 %
Rural 54,116 5,923 (11 %) 3,397 (6 %) 2,004 (4 %) 59 %
Unknown 1,354 205 (15 %) 104 (8 %) 49 (4 %) 47 %
Total
300,188 29,857(10 %) 16,091 (5 %) 9,013 (3 %) 56 %
aIncludes willing but ineligible responses. Eligibility likely to vary in subgroups due to differing incidence of prior vascular disease
bBased on age on the date screening invitation generated
cBased on postcode at screening (lower values indicate least deprived). Score unknown for 557 of those invited
dBased on postcode at screening (using ONS 2011 Rural-Urban Classification for Small Area Geographies)
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calls made by study staff, typically to clarify information
that had been written on the screening and randomisa-
tion questionnaires. Approximately half of all telephone
calls (both outgoing and incoming) related to partici-
pants who were not subsequently randomised.
Blood and urine kits were sent to 22,858 patients who
entered the pre-randomisation phase and who had not
informed the coordinating centre that they wished to
withdraw before the kits were due to be sent. Samples
(either blood or urine or both) were received by the
laboratory from 13,270 individuals, among whom 11,685
were subsequently randomised. The average delay be-
tween sample collection and receipt at the coordinating
centre laboratory (sent by first class post to limit sample
delays) was 2 days.
Discussion
ASCEND is one of the largest ever randomised trials
among people with diabetes. It achieved its recruitment
target of 15,000 participants by means of central and local
diabetes registers to identify patients who might be suitableand by using highly cost-effective mail-based systems to
send screening and randomisation questionnaires, provide
study drugs, and collect biological samples. The trial is
funded by a grant to the University of Oxford from the
British Heart Foundation (£3.7 million), which covers the
costs of running the study over a 15-year period (to include
planning, recruitment, follow-up, and study close-out and
reporting activities). Within this budget, the costs of print-
ing and postage for the mail-based recruitment process
were less than £0.5 million, which is substantially less than
the clinic staff costs that would be required for a standard
clinic-based approach at this large scale. Study drug and
additional funding for drug packaging (£3.6 million) was
provided by Bayer and Solvay Pharmaceuticals (subse-
quently Abbott, and now Mylan). In addition, the 668 prac-
tices identified via the DRN and PCRN were eligible for
local network support funding (typically around £500 per
practice) to help with recruitment activities. Overall, the
total costs of this major trial are therefore an order of mag-
nitude lower than those of a typical commercial clinic-
based study (generally at least £3–400 M for large clinical
outcome trials [4]).
Fig. 5 Location of randomised participants in the UK (postcode of home address)
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ticipants has been possible from the information collected
on the mailed screening and randomisation questionnaires
and from mailed blood and urine samples. ASCEND illus-
trates that if large enough numbers of potentially eligible
patients can be identified, and automated methods can be
adopted, it is possible to recruit a large study population
successfully by mail.
Access to centrally held registers of potentially eligible
patients was crucial to the success of recruitment into
ASCEND. Although this required the transfer of patient-
identifiable information from the register holder to the
coordinating centre without the patient’s prior consent,
existing legislation allows this to be done within a strict
legal framework. Without access to these registries, more
than 2000 GP practices would need to have been identifiedand, even if this had been possible, such an approach would
have increased the costs and time to recruit significantly.
Previous patient volunteer focus group work conducted by
CTSU for other studies has confirmed that most patients
find this approach acceptable, as long as robust information
governance standards are adhered to.
In ASCEND, a small number of complaints were re-
ceived about the transfer of data without consent. In
the majority of cases, the complainant was unaware of
the relevant legislation, and a simple verbal explanation
of the process was sufficient to clarify any concerns,
with many such individuals subsequently agreeing to
join the trial. The complainant remained dissatisfied in
only 28 cases (0.01 % of 300,188 people invited from
centrally held registers) and requested removal of per-
sonal data from the study database. The coordinating
Aung et al. Trials  (2016) 17:286 Page 10 of 12centre had a standard operating procedure for such re-
quests, which were acted on promptly. Whereas previ-
ous mail-based trials had successfully recruited from
populations of healthcare professionals [5–8], ASCEND
has demonstrated the acceptability of this approach in
a general diabetic population.
Overall, less than one-third of those invited replied to
the invitation to take part, and the majority of those who
did reply declined to join the study. Other groups have
reviewed possible methods to improve the response to
postal and electronic questionnaires in order to identify
effective strategies to improve recruitment to trials and
epidemiological studies. A Cochrane review reported sub-
stantial heterogeneity among trials, evaluating more than
100 different approaches to increasing the response to
postal questionnaires (typically for epidemiological stud-
ies) [11]. Strategies involving monetary incentives and the
use of recorded delivery of the questionnaire appeared to
be successful, approximately doubling the response rate to
postal questionnaires. However, such approaches would
add substantially to the cost of a large trial such as
ASCEND. Furthermore, those recruited by means of fi-
nancial incentives might not remain adequately compliant
with follow-up and study treatment in longer-term stud-
ies. Sending reminders in ASCEND was an effective strat-
egy, which substantially improved the response rate,
without which, an additional 140,000 potentially eligible
people would have needed to be invited.
Follow-up in ASCEND is ongoing, using mail-based ap-
proaches supplemented by central registry data. Study par-
ticipants receive requests every 6 months for follow-up
information. This can be provided either by means of a
paper questionnaire, by telephone to the coordinating
centre, or using a web-based interface via an internet
browser, according to the individual’s preference. For par-
ticipants who are no longer able or willing to complete
questionnaires, follow-up information is obtained from
their GP. Overall, good rates of follow-up are being
achieved using these cost-effective methods. At present,
approximately 95 % of all live study participants have
follow-up information available from within the last
12 months, and efforts are ongoing to contact those par-
ticipants for whom follow-up is due.
The currently observed compliance (blinded) with the
aspirin/placebo study treatment at the end of the first
year post-randomisation is approximately 85 %, with a
further 5–7 % decline in compliance annually thereafter.
Despite participants having no routine direct contact
with the study team, this is comparable to clinic-based
trials in similar populations [12]. However, notably, the
compliance with study treatments is somewhat lower
among those who were sent a reminder randomisation
form compared with those who replied to the initial
mailing. For example, at the study mid-point (45 monthsafter randomisation), 61 % of those sent a randomisation
reminder were compliant with their aspirin/placebo
study tablets versus 68 % of those where no reminder
was sent (p < 0.0001). This reduction in compliance became
apparent within the first 6 months after randomisation and,
although reminders were essential for the completion of
recruitment, the implications for reduced compliance in
those who do not readily respond to questionnaire mailings
is an important consideration.
On the other hand, the use of a pre-randomisation
run-in is a valuable methodological tool to enhance
compliance, especially in the early phase of a long-term
study [10]. Of those who entered the single-blind pla-
cebo run-in period in ASCEND, approximately 40 %
dropped out of the study before randomisation. Had
there been no run-in, these withdrawals would probably
have occurred after randomisation (most likely in the
first 6–12 months), thereby substantially reducing the
statistical power of the study.
Recruitment into ASCEND took longer than initially
hoped as a result of a variety of factors, including research
governance delays [13], the time taken to obtain the elec-
tronic records from the diabetes registers, establishing ro-
bust IT systems to monitor the study, and an increase in
the original recruitment target. However the involvement
of the former local NIHR Diabetes and Primary Care Re-
search Networks across England and Scotland provided a
valuable extra resource, which boosted recruitment and,
had they been established sooner, might have shortened the
recruitment period. A substantial infrastructure for pa-
tient recruitment to research studies continues to be
available through the NIHR Clinical Research Network.
The response to invitation was higher among those
identified from general practice compared with those in
central registries (5 % vs 3 % of those invited were
eventually randomised). This may have been partly due
to the ability to pre-screen potential participants to ex-
clude those with established vascular disease but also
because participants were more likely to respond posi-
tively to a GP whom they knew.
The design of ASCEND included an optional baseline
blood and urine sample collection during the pre-
randomisation run-in phase. This exercise was funded
by a separate project grant from the British Heart Foun-
dation (£140 k). Previous transport studies have demon-
strated that a wide range of analytes (including HbA1c
lipids and cystatin C as a measure of renal function) and
genetic polymorphisms can be reliably measured in
whole blood samples with delayed separation [14, 15].
During the past few years, extensive experience has been
gained with obtaining cardiovascular risk factor mea-
surements from mailed blood samples [16]. In ASCEND,
this approach has allowed measured baseline risk factor
information to be obtained from 75 % of those
Aung et al. Trials  (2016) 17:286 Page 11 of 12randomised at very low cost, which will allow the effects
of the study treatments to be assessed within subgroups
defined by biological measures.
Conclusions
ASCEND is designed to be streamlined and highly cost-
effective. When completed, the trial will have cost < £10
million overall. This includes both the NHS service sup-
port costs provided to general practices and the substan-
tial costs of drug packaging and distribution (which are
typically covered by the pharmaceutical industry and not
usually included in the budget quoted for many large-
scale outcome studies). Using the methods described,
ASCEND has randomised nearly 15,500 people with dia-
betes, making it one of the largest ever randomised trials
in this patient group. The questions it aims to address are
clinically relevant for the hundreds of millions of people
worldwide with diabetes and, with good follow-up and
compliance, will add valuable information on the balance
of benefits and risks of these treatments, including im-
portant data on the use of aspirin for cancer prevention.
The strategies which helped make recruitment successful
include (1) simple inclusion and exclusion criteria, (2) the
central coordination of recruitment, (3) the ability to iden-
tify a large pool of potentially eligible people, and (4) the
involvement of local research networks. The success of
these methods in ASCEND show that, with good plan-
ning, mail-based methodology is cost-effective and could
be more widely adopted for the assessment of interven-
tions that require little monitoring.
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